Ex Vivo Treatment By Mitapivat, an Allosteric Pyruvate Kinase Activator, Reduced Hemolysis and Reactive Oxygen Species in Red Blood Cells of Non-Transfusion Dependent Hemolytic Anemic Patients Due to β-Thalassemia/Hb E Disease

Introduction: The β-thalassemia/Hemoglobin E (β-thal/Hb E) disease, an inherited disorder that combines the β-globin gene mutations, including β^o and β⁺, and the Hb E variant, is frequently found in Southeast Asian populations, including Thailand. Pathophysiology of red blood cells (RBCs) of anemic patients with β-thal/Hb E is caused by a reduction of β-globin synthesis from β^o or β⁺mutations leading to an unbalanced excess of α-globin chains. Free α-globin chains trigger a cascade of events through generation of intracellular reactive oxygen species (ROS) leading to peripheral RBC hemolysis, resulting in the moderate severity of β-thal/Hb E. Mitapivat (AG-348), an allosteric activator of pyruvate kinase (PK), is being evaluated for its efficacy and safety as a potential therapy for the treatment of thalassemia (NCT04770753 and NCT04770779). We are currently studying the effects of mitapivat on RBC pathophysiology and production of adenosine triphosphate (ATP), the energy carrier molecule derived from the glycolytic pathway by PK activity, in the RBCs of β-thal/Hb E patients.

Objective: To evaluate the effects of mitapivat on RBC pathophysiology, including intracellular ROS, hemolysis, and ATP production, in RBCs of non-transfusion dependent hemolytic anemia patients with β-thal/Hb E disease (NTDT) in an ex vivo setting.

Methods: A 2-mL EDTA whole blood sample was collected from non-regularly transfused patients who were diagnosed with β-thal/Hb E disease by multiplex PCR methods to specifically detect 9 common β-globin gene mutations found in the Thai population. RBCs were separated by an α-cellulose bead column and prepared into a suspension of 1 x 10⁷ RBCs/mL in a complete culture medium. RBC suspension was incubated with mitapivat (Agios Pharmaceuticals, Inc.) at 37⁰C for 24 h. The mitapivat-treated RBCs were harvested to measure ATP levels. Oxidative stress was evaluated by measuring the mean fluorescent intensity (MFI) of intracellular ROS. The culture medium was collected to measure the Hb released, which represented RBC hemolysis.

Results: The 25 non-regularly transfused patients with β-thal/Hb E disease, including 20 and 5 cases with β^oβ^E and β⁺β^E genotypes, respectively, had chronic anemia with the mean (± standard deviation; SD) Hb concentration of 8.0±0.6 and 8.9±1.0 gm/dL, respectively. After treatment with various concentrations between 0.002 to 10 μM mitapivat, the ATP level detected in the RBCs of patients with β^oβ^E and β⁺β^E genotypes significantly increased in a concentration-dependent manner from 100% to 140% and from 100% to 120%, respectively, compared to the baseline ATP level of 0.1% DMSO solvent control. The MFI of ROS in mitapivat-treated β^oβ^E and β⁺β^E RBCs decreased from 90% to 70% compared to baseline MFI of solvent control, indicating a reduction in oxidative stress. Moreover, reduced intracellular ROS found in mitapivat-treated RBCs corresponded to reduced hemolysis as reflected by Hb released from treated RBCs in the culture medium. A decrease in the amount of Hb released (µg/mL) in a concentration-dependent manner was found from 90% to 70% compared to the baseline Hb released of solvent control.

Conclusion: This ex vivo study showed that mitapivat could reduce hemolysis and decrease intracellular ROS in RBCs of non-transfusion dependent β-thal/Hb E disease patients presented with moderately to severe hemolytic anemia. Moreover, mitapivat promoted ATP production, which supported energy for RBC survival in the blood of β-thal/Hb E patients. Data obtained from this study supports the current clinical trials of mitapivat in thalassemia to ameliorate clinical anemia in patients due to β-globin gene mutations by improving RBC physiology and decreasing peripheral hemolysis.

Viprakasit:Vifor: Research Funding; The Government Pharmaceutical Organization: Research Funding; Pharmacosmos: Research Funding; Agios Pharmaceuticals, Inc.: Research Funding; Bristol Myers Squibb (Celgene): Research Funding; DisperSol Technologies: Research Funding; Ionis Pharmaceuticals: Research Funding; Novartis: Research Funding.